Answer extracted from the 16 Minutes News by a16z podcast — listen to the full episode below.
How does the R21 malaria vaccine work through virus-like particles?
The R21 vaccine uses virus-like particles derived from hepatitis B surface antigen as a scaffolding base that presents malaria antigens to the immune system. This triggers both antibody and cell-mediated immune responses that allow the body to recognize and fight the parasite. The Oxford vaccine achieves higher efficacy by incorporating proportionally more malaria protein on each particle compared to earlier vaccine designs.
Virus-like particles: The immune system's training ground
Virus-like particles (VLPs) are essentially hollow shells that mimic the structure of real viruses without containing genetic material or infectious capability. In the case of R21, the hepatitis B surface antigen serves as the core particle, providing a familiar structure that the immune system recognizes as a threat. This scaffold allows malaria antigens to be displayed in an organized, repeating pattern—exactly how they appear on the actual parasite.
This presentation method is crucial because it triggers a sophisticated immune response. When the immune system encounters these antigen-displaying particles, it mobilizes both humoral immunity (antibody production) and cellular immunity (helper T cell and killer T cell activation). As Rajiv Venkayya explains in this episode, the sophistication of the immune system matters enormously when tackling parasitic diseases—if the immune system cannot generate protection on its own, vaccine design becomes exponentially more challenging.
Why Oxford's formulation outperforms earlier attempts
The R21 vaccine's breakthrough came partly from refinement in antigen density. The vaccine contains significantly more malaria protein relative to the particle core than GlaxoSmithKline's earlier RTSS vaccine, which showed only 56 percent initial efficacy in year one, declining to 36 percent after four years. This denser payload of antigen material appears to generate a more robust immune memory.
In phase 2B trials with 450 children aged 5 to 17 months in Burkina Faso, R21 demonstrated 77 percent efficacy over 12 months—a substantial leap toward the World Health Organization's 75 percent target for future malaria vaccines. The phase 3 trial is currently recruiting 4,800 children across four African countries to confirm these results and establish the vaccine's real-world impact.
"The immune system, which is super sophisticated, is not able to do that, then almost by definition, it's going to be a tough vaccine problem."
Rajiv Venkayya — President of the Global Vaccine Business Unit at Takeda Pharmaceuticals. A medical doctor who leads development of vaccines for tropical diseases including dengue, norovirus, and Zika, Venkayya previously directed vaccine delivery initiatives at the Gates Foundation and advised the White House on biodefense strategy.
What makes this particle-based approach particularly relevant is its contrast to viral vector vaccines (like those using adenoviruses as delivery vehicles). Virus-like particles eliminate the risk of pre-existing immunity or integration into the human genome—concerns that constrained some COVID-19 vaccine development. For a disease with the complexity of malaria, where 229 million clinical cases were reported in the year before this episode aired, the safety profile of VLP-based vaccines adds another layer of confidence.
Key takeaways
- R21 uses hepatitis B surface antigen particles as a platform to display malaria antigens in a pattern the immune system recognizes.
- The vaccine triggers both antibody responses and cell-mediated immunity—a two-pronged defense against the parasite.
- Higher malaria protein density on each particle contributes to R21's 77 percent efficacy versus 56 percent for earlier RTSS vaccine designs.
- Virus-like particles offer a safer alternative to viral vectors, with no genetic integration risk and no concern about pre-existing immunity.
See also
Why is malaria considered one of the most difficult diseases to develop a vaccine against?
Malaria is one of the big three diseases alongside HIV and tuberculosis that cause extraordinary suffering and deaths yearly. The parasite is inherently complex, with multiple life stages and sophisticated immune evasion mechanisms that make generating durable protective immunity exceptionally difficult.